LAVA Therapeutics N.V.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company based in Utrecht, Netherlands, specializing in the development of innovative cancer therapies using its proprietary Gammabody platform that engineers bispecific gamma delta T cell engagers designed to selectively target and kill cancer cells by activating Vγ9Vδ2 T cell antitumor functions. Its product portfolio includes several clinical-stage bispecific antibodies such as LAVA-051 for hematological malignancies including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, and LAVA-1207 for metastatic castration-resistant prostate cancer, alongside other candidates addressing solid tumors and diverse cancer types. Founded in 2016, LAVA Therapeutics focuses on harnessing gamma delta T cells' unique capabilities to improve cancer treatment efficacy with reduced toxicity and operates primarily in the immuno-oncology biotechnology sector serving global markets. Recently, in November 2025, LAVA Therapeutics was acquired by XOMA Royalty Corporation in a strategic transaction that incorporated LAVA’s early-stage bispecific antibody assets—developed in collaboration with major oncology partners Johnson & Johnson and Pfizer—into XOMA’s milestone and royalty portfolio, leading to LAVA’s delisting from Nasdaq and signaling a major operational and ownership change with potential for significant value creation from future royalties and milestones associated with LAVA's programs. This acquisition aligns with XOMA’s strategy to expand its oncology portfolio and strengthens the commercial prospects of LAVA’s Gammabody-based therapies through enhanced collaborative development and royalty revenue opportunities.
LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts
Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69
Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement
LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LAVA Reports Second Quarter 2024 Financial Results and Business Update
4 Stocks Under $5 To Buy Now